Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Potent Promise

Recent approvals have established the viability of antibody-drug conjugates, and open the door to future products that are more efficacious, better tolerated and applicable to broader patient populations.

Donald Bergstrom, Timothy Lowinger and Peter Park, Mersana Therapeutics (June 2014)

Keywords: Antibody-drug conjugates, DNA damaging agents, Tubulin binder, Drug-to-antibody ratio, Potent drug payloads

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |